dronedarone (multaq) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reactions include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.   NCATS

Chemistry

  • SMILES: CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c(CCCC)oc3ccc(NS(=O)(=O)C)cc23
  • InChIKey: ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
  • Mol. Mass: 556.77
  • ALogP: 7.05
  • ChEMBL Molecules:
    dronedarone  
    dronedarone hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$7.9384 - $10.5121
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dronedarone | dronedarone hcl | dronedarone hydrochloride | multaq | n-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide | n-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide | sr 33589 | sr 33589b | sr33598b | sr-33598b

Organizations (37)

Research & Development (28)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (2)


 

Atrial Fibrillation

Atrial Flutter (approved 2009)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Atrial Fibrillation (Phase 4)

Atrial Flutter (Phase 3)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 3)

Postoperative Complications (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial Organizations: 28

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue